ADMA
Adma Biologics Inc
$2.43
+0.01 (+0.41%)
quotes and stock data delayed 15 minutes
52 wk hi
52 wk low
1.5
4.16
Cash
$59.7M
Burn Rate (Qtr)
$16.9M
Mkt Cap
$229.8m
Avg Volume
3,804,450
*cash/burn updated:
Q3'20
Company Profile
ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA’s lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was accepted by the FDA on September 18, 2015. The company has received U.S. Patent 9,107,906. For more information, please visit the company's website at www.admabiologics.com.
Drug Pipeline
Click on drug name or indication to see upcoming trial info, prior data, and more general information
Drug | Disease (links)
Stage (next event)
Catalyst Date
Recent Posts
See what the community is saying - click to see full post